Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood

Area of Science:

• Pediatric Oncology
• Hematology
• Molecular Biology

Background:

• The pre-B-cell (clgM) phenotype accounts for approximately 20% of childhood acute lymphoblastic leukemia (ALL) cases.
• This phenotype is frequently associated with chromosomal translocations, particularly t(1;19)(q23;p13).
• Historically, this ALL subtype has been linked to poor treatment outcomes and high-risk features.

Purpose of the Study:

• To investigate the prognostic implications of the pre-B-cell ALL phenotype, specifically the t(1;19) translocation.
• To explore the impact of aggressive treatment strategies on outcomes for patients with t(1;19) ALL.
• To highlight recent molecular insights into the pathogenesis of pre-B-cell ALL and the potential of molecular diagnostics.

Main Methods:

• Phenotypic analysis of childhood ALL cases.
• Cytogenetic analysis to identify chromosomal translocations, including t(1;19).
• Review of treatment outcomes and prognostic factors.
• Molecular analyses including recombinant DNA technology (polymerase chain reaction).

Main Results:

• The t(1;19) translocation is a primary driver of the poor prognosis previously associated with the pre-B-cell ALL phenotype.
• Preliminary data suggest that intensive treatment regimens may mitigate the adverse prognostic impact of the t(1;19) translocation.
• Molecular studies are providing novel insights into the pathogenesis of t(1;19) ALL.

Conclusions:

• The t(1;19) translocation is the key adverse prognostic factor in pre-B-cell ALL.
• Aggressive therapeutic approaches show promise in improving outcomes for patients with t(1;19) ALL.
• Advances in molecular diagnostics, such as PCR, are expected to enhance diagnosis and minimal residual disease detection for this ALL subtype.